Literature DB >> 18524891

Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness.

Núria de la Iglesia1, Genevieve Konopka, Kah-Leong Lim, Catherine L Nutt, Jacqueline F Bromberg, David A Frank, Paul S Mischel, David N Louis, Azad Bonni.   

Abstract

Inactivation of the tumor suppressor phosphatase and tensin homolog (mutated in multiple advanced cancers 1) (PTEN) is recognized as a major event in the pathogenesis of the brain tumor glioblastoma. However, the mechanisms by which PTEN loss specifically impacts the malignant behavior of glioblastoma cells, including their proliferation and propensity for invasiveness, remain poorly understood. Genetic studies suggest that the transcription factor signal transducers and activators of transcription 3 (STAT3) harbors a PTEN-regulated tumor suppressive function in mouse astrocytes. Here, we report that STAT3 plays a critical tumor suppressive role in PTEN-deficient human glioblastoma cells. Endogenous STAT3 signaling is specifically inhibited in PTEN-deficient glioblastoma cells. Strikingly, reactivation of STAT3 in PTEN-deficient glioblastoma cells inhibits their proliferation, invasiveness, and ability to spread on myelin. We also identify the chemokine interleukin 8 (IL8) as a novel target gene of STAT3 in human glioblastoma cells. Activated STAT3 occupies the endogenous IL8 promoter and directly represses IL8 transcription. Consistent with these results, IL8 is upregulated in PTEN-deficient human glioblastoma tumors. Importantly, IL8 repression mediates STAT3 inhibition of glioblastoma cell proliferation, invasiveness, and spreading on myelin. Collectively, our findings uncover a novel link between STAT3 and IL8, the deregulation of which plays a key role in the malignant behavior of PTEN-deficient glioblastoma cells. These studies suggest that STAT3 activation or IL8 inhibition may have potential in patient-tailored treatment of PTEN-deficient brain tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18524891      PMCID: PMC2700037          DOI: 10.1523/JNEUROSCI.5385-07.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  34 in total

1.  Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells.

Authors:  Shaik Ohidar Rahaman; Phyllis C Harbor; Olga Chernova; Gene H Barnett; Michael A Vogelbaum; S Jaharul Haque
Journal:  Oncogene       Date:  2002-12-05       Impact factor: 9.867

2.  IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways.

Authors:  I U Schraufstatter; J Chung; M Burger
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-06       Impact factor: 5.464

3.  Stat3 as an oncogene.

Authors:  J F Bromberg; M H Wrzeszczynska; G Devgan; Y Zhao; R G Pestell; C Albanese; J E Darnell
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

Review 4.  STATs in oncogenesis.

Authors:  T Bowman; R Garcia; J Turkson; R Jove
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

Review 5.  Gliomagenesis: genetic alterations and mouse models.

Authors:  E C Holland
Journal:  Nat Rev Genet       Date:  2001-02       Impact factor: 53.242

Review 6.  Signaling pathways regulating gliomagenesis.

Authors:  G Konopka; A Bonni
Journal:  Curr Mol Med       Date:  2003-02       Impact factor: 2.222

7.  Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2.

Authors:  Jan Heidemann; Hitoshi Ogawa; Michael B Dwinell; Parvaneh Rafiee; Christian Maaser; Henning R Gockel; Mary F Otterson; David M Ota; Norbert Lugering; Wolfram Domschke; David G Binion
Journal:  J Biol Chem       Date:  2002-12-20       Impact factor: 5.157

8.  Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB.

Authors:  Zhiyuan Yu; Wenzheng Zhang; Bruce C Kone
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

9.  Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.

Authors:  Lene Uhrbom; Chengkai Dai; Joseph C Celestino; Marc K Rosenblum; Gregory N Fuller; Eric C Holland
Journal:  Cancer Res       Date:  2002-10-01       Impact factor: 12.701

10.  Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis.

Authors:  Robert M Bachoo; Elizabeth A Maher; Keith L Ligon; Norman E Sharpless; Suzanne S Chan; Mingjian James You; Yi Tang; Jessica DeFrances; Elizabeth Stover; Ralph Weissleder; David H Rowitch; David N Louis; Ronald A DePinho
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

View more
  74 in total

1.  Cerebrospinal fluid and serum IL-8, CCL2, and ICAM-1 concentrations in astrocytic brain tumor patients.

Authors:  O M Koper; J Kamińska; K Sawicki; J Reszeć; R Rutkowski; M Jadeszko; Z Mariak; V Dymicka-Piekarska; H Kemona
Journal:  Ir J Med Sci       Date:  2017-10-30       Impact factor: 1.568

2.  A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Authors:  Elisa Pin; Steven Stratton; Claudio Belluco; Lance Liotta; Ray Nagle; K Alex Hodge; Jianghong Deng; Ting Dong; Elisa Baldelli; Emanuel Petricoin; Mariaelena Pierobon
Journal:  Mol Oncol       Date:  2016-10-14       Impact factor: 6.603

Review 3.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

4.  miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.

Authors:  Nicola Amodio; Dina Bellizzi; Marzia Leotta; Lavinia Raimondi; Lavinia Biamonte; Patrizia D'Aquila; Maria Teresa Di Martino; Teresa Calimeri; Marco Rossi; Marta Lionetti; Emanuela Leone; Giuseppe Passarino; Antonino Neri; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Cell Cycle       Date:  2013-09-25       Impact factor: 4.534

Review 5.  STAT3 regulation of glioblastoma pathogenesis.

Authors:  Núria de la Iglesia; Sidharth V Puram; Azad Bonni
Journal:  Curr Mol Med       Date:  2009-06       Impact factor: 2.222

Review 6.  Interleukins in glioblastoma pathophysiology: implications for therapy.

Authors:  Y T Yeung; K L McDonald; T Grewal; L Munoz
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

7.  Mutant tristetraprolin: a potent inhibitor of malignant glioma cell growth.

Authors:  Esther A Suswam; John J Shacka; Kiera Walker; Liang Lu; Xuelin Li; Ying Si; Xiaowen Zhang; Lei Zheng; L Burt Nabors; Heping Cao; Peter H King
Journal:  J Neurooncol       Date:  2013-03-25       Impact factor: 4.130

8.  Dynamic, large-scale profiling of transcription factor activity from live cells in 3D culture.

Authors:  Michael S Weiss; Beatriz Peñalver Bernabé; Abigail D Bellis; Linda J Broadbelt; Jacqueline S Jeruss; Lonnie D Shea
Journal:  PLoS One       Date:  2010-11-17       Impact factor: 3.240

9.  Molecular mechanisms of HIF-1alpha modulation induced by oxygen tension and BMP2 in glioblastoma derived cells.

Authors:  Francesca Pistollato; Elena Rampazzo; Sara Abbadi; Alessandro Della Puppa; Renato Scienza; Domenico D'Avella; Luca Denaro; Geertruy Te Kronnie; David M Panchision; Giuseppe Basso
Journal:  PLoS One       Date:  2009-07-09       Impact factor: 3.240

10.  ATP stimulates chemokine production via a store-operated calcium entry pathway in C6 glioma cells.

Authors:  Nattinee Jantaratnotai; Hyun B Choi; James G McLarnon
Journal:  BMC Cancer       Date:  2009-12-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.